GENVEC INC
GENVEC INC (GNVC): 8 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.4 months
D/E 7.42 · 0% dilution
Lead: Phase 2
8 candidates
N/A
N/A
A transparent, data-derived signal for GENVEC INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$2.5M
Quarterly Burn
$2.8M
Runway
3.4 mo
Revenue
$114K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| cgf166 | Phase 2 |
| ev-d68 vaccine | Preclinical |
| fmd vaccine | Preclinical |
| gv2207 | Preclinical |
| gv2311 | Preclinical |
| hsv vaccine | Preclinical |
| malaria vaccine | Preclinical |
| rsv vaccine | Preclinical |
Frequently asked questions
How many drug candidates are in GENVEC INC's pipeline?
GENVEC INC (GNVC) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is GENVEC INC's lead drug candidate?
GENVEC INC's most advanced tracked candidate is cgf166 (Phase 2) for hearing loss and balance disorders.
What is GENVEC INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, GENVEC INC has approximately 3.4 months of cash runway.
Who is the CEO of GENVEC INC?
Douglas J. Swirsky is the chief executive officer of GENVEC INC (GNVC).
Get the full picture on GENVEC INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.